Expertise in
5
conditions

Dr. Bora R. Lim

Houston, TX
Expertise in
5
conditions
Specialties:Oncology | Hematology | Hematology Oncology
Accepting New Patients
Expertise in
5
conditions
OverviewInsuranceLocationsClinical Research

Overview

Bora Lim is an Oncologist and a Hematologist in Houston, Texas. Dr. Lim is highly rated in 5 conditions, according to our data. Her top areas of expertise are Inflammatory Breast Cancer, Breast Cancer, Triple-Negative Breast Cancer, Paget Disease of the Breast, and Tissue Biopsy. Dr. Lim is currently accepting new patients.

Her clinical research consists of co-authoring 158 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Hematology Oncology
Licenses
Internal Medicine in TX
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Community Health
  •  UnitedHealthcare
  •  Humana

Locations

MD Anderson
2130 W Holcombe Blvd, Life Sciences Plaza, Houston, TX 77030
713-592-5433

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

TBCRC 042 - a Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions
TBCRC 042 - a Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions
Enrollment Status: Active_not_recruiting
Publish Date: February 14, 2025
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
A Phase II Study of Anti-PD-1 (Pembrolizumab) in Combination With Hormonal Therapy During or After Radiation in Patients With Hormone Receptor (HR)-Positive Localized Inflammatory Breast Cancer (IBC) Who Did Not Achieve a Pathological Complete Response (pCR) to Neoadjuvant Chemotherapy
A Phase II Study of Anti-PD-1 (Pembrolizumab) in Combination With Hormonal Therapy During or After Radiation in Patients With Hormone Receptor (HR)-Positive Localized Inflammatory Breast Cancer (IBC) Who Did Not Achieve a Pathological Complete Response (pCR) to Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2025
Intervention Type: Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy
Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Biological, Drug
Study Drugs: Carboplatin, Paclitaxel, Panitumumab
Study Phase: Phase 2
A Phase II Study of Anti-PD-1 (MK-3475) Therapy in Patients With Metastatic Inflammatory Breast Cancer (IBC) or Non-IBC Triple Negative Breast Cancer (TNBC) Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
A Phase II Study of Anti-PD-1 (MK-3475) Therapy in Patients With Metastatic Inflammatory Breast Cancer (IBC) or Non-IBC Triple Negative Breast Cancer (TNBC) Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 09, 2025
Intervention Type: Other, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase 1b Study of Neratinib, Pertuzumab, and Trastuzumab With Taxol (3HT) in Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBC
A Phase 1b Study of Neratinib, Pertuzumab, and Trastuzumab With Taxol (3HT) in Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBC
Enrollment Status: Active_not_recruiting
Publish Date: December 13, 2024
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin, Neratinib, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 1/Phase 2
A Phase II Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) or Atezolizumab + Eribulin (AE) in Patients With Recurrent/Metastatic Inflammatory Breast Cancer
A Phase II Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) or Atezolizumab + Eribulin (AE) in Patients With Recurrent/Metastatic Inflammatory Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2024
Intervention Type: Drug, Other
Study Drugs: Atezolizumab, Cobimetinib, Eribulin
Study Phase: Phase 2
A Phase IIB Study of Neoadjuvant ZT Regimen (Enzalutamide Therapy in Combination With Weekly Paclitaxel) for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer
A Phase IIB Study of Neoadjuvant ZT Regimen (Enzalutamide Therapy in Combination With Weekly Paclitaxel) for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Procedure, Other, Drug
Study Drugs: Enzalutamide, Paclitaxel
Study Phase: Phase 2
A Multi-national,Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel®,Oral Paclitaxel) Compared to IV Paclitaxel in Patients With Recurrent or Metastatic Breast Cancer(OPERA)
A Multi-national,Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel®,Oral Paclitaxel) Compared to IV Paclitaxel in Patients With Recurrent or Metastatic Breast Cancer(OPERA)
Enrollment Status: Completed
Publish Date: February 16, 2024
Intervention Type: Drug
Study Drugs: DHP107, Paclitaxel
Study Phase: Phase 2
A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry
A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry
Enrollment Status: Completed
Publish Date: September 28, 2022
Intervention Type: Drug
Study Phase: Phase 2
Phase II Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer
Phase II Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: October 07, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

159 Total Publications

Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity.
Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity.
Journal: Journal for immunotherapy of cancer
Published: November 18, 2024
Similar Doctors
Expertise in
43
conditions
Dr. Tapan M. Kadia
Hematology | Oncology | Hematology Oncology
Expertise in
43
conditions
Dr. Tapan M. Kadia
Hematology | Oncology | Hematology Oncology

MD Anderson

2130 W Holcombe Blvd, Life Sciences Plaza, 
Houston, TX 
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tapan Kadia is a Hematologist and an Oncologist in Houston, Texas. Dr. Kadia is highly rated in 43 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

Nitin B. Jain
Expertise in
35
conditions
Dr. Nitin B. Jain
Hematology | Oncology | Hematology Oncology
Expertise in
35
conditions
Dr. Nitin B. Jain
Hematology | Oncology | Hematology Oncology

MD Anderson

2130 W Holcombe Blvd, Life Sciences Plaza, 
Houston, TX 
713-592-5433
Languages Spoken:
English
See accepted insurances

Nitin Jain is a Hematologist and an Oncologist in Houston, Texas. Dr. Jain is highly rated in 35 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Acute Lymphoblastic Leukemia (ALL), Chronic B-Cell Leukemia (CBCL), Bone Marrow Aspiration, and Endoscopy.

Elias J. Jabbour
Expertise in
37
conditions
Dr. Elias J. Jabbour
Hematology Oncology | Hematology | Oncology
Expertise in
37
conditions
Dr. Elias J. Jabbour
Hematology Oncology | Hematology | Oncology

MD Anderson

2130 W Holcombe Blvd, Life Sciences Plaza, 
Houston, TX 
713-592-5433
Languages Spoken:
English
See accepted insurances

Elias Jabbour is a Hematologist Oncology specialist and a Hematologist in Houston, Texas. Dr. Jabbour is highly rated in 37 conditions, according to our data. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile